Serelaxin (Recombinant Relaxin-2) Dosage Chart & Schedule
Serelaxin is recombinant human relaxin-2 (RLX030) studied mainly as a short intravenous infusion in acute heart failure. After early promise, the large RELAX-AHF-2 trial did not meet its primary endpoints, and the compound remains investigational and unapproved. Human data therefore exist but are ultimately negative for its lead indication.
Serelaxin is recombinant human relaxin-2 studied as a continuous 48-hour IV infusion in acute heart failure, dosed at 30 mcg/kg/day. The large RELAX-AHF-2 trial did not meet its primary endpoints, so human data exist but are ultimately negative for its lead indication; it remains investigational.
Figures describe how Serelaxin (Recombinant Relaxin-2) is reported in the research literature and research-community references — not a recommendation for human use. For laboratory research only.
Dosage protocols
Commonly referenced research tiers. Start conservative; every compound and study context differs.
- Frequency
- Continuous 48-hour IV infusion
- Weekly total
- A single 48-hour course, not a weekly total
- Cycle
- One acute-heart-failure hospitalization course (RELAX-AHF trials)
RELAX-AHF-2 did not meet its primary endpoints; investigational, not recommended.
Trial outcome was negative
- After early promise, the large RELAX-AHF-2 trial did not meet its primary endpoints.
- It was given as a continuous 48-hour IV infusion at 30 mcg/kg/day in acute heart failure.
- It remains investigational and unapproved.
Not a self-injectable
- It is a hospital-administered IV biologic, not a bacteriostatic-water subcutaneous product.
- Dosing is weight-based (mcg/kg/day) over a fixed 48-hour window.
Ready to run this protocol?
Dosing is only as good as the vial. Research-grade peptides are third-party tested with published COAs from our top-rated source — reconstitute with confidence and skip the guesswork on identity and purity.
From vial to injection in 6 steps
Wipe both vial tops
Swab the peptide vial and the bacteriostatic-water vial with fresh alcohol and let them dry.
Draw the water
Pull the planned amount of bacteriostatic water (per your mix) into the syringe.
Add it slowly
Run the water down the inside wall of the vial — don't blast the powder. Swirl gently; never shake.
Let it dissolve
Wait until the solution is fully clear, then refrigerate the vial.
Draw your dose
Pull the calculated units on a U-100 insulin syringe.
Store between uses
Keep the reconstituted vial refrigerated and use within its stable window.
Handling & storage
- Not a bacteriostatic-water subcutaneous injectable; it is an IV biologic.
- In trials it was prepared and diluted for a continuous 48-hour infusion in hospital.
- Dosing was weight-based at 30 mcg/kg/day over the 48 hours.
- Investigational; handled only in clinical or research settings.
Serelaxin (Recombinant Relaxin-2) dosing FAQ
How was serelaxin dosed in trials?
The RELAX-AHF program used 30 mcg/kg/day as a continuous 48-hour IV infusion in acute heart failure, not as bolus injections. This is investigational context, not a recommendation.
Can it be dosed subcutaneously like other peptides?
No. It was studied as a hospital IV infusion, not a bacteriostatic-water subcutaneous product, and it is not approved.
What did the trials show?
After early promise, the large RELAX-AHF-2 trial did not meet its primary endpoints, so the outcome for its lead indication was ultimately negative.
How much drug is 30 mcg/kg/day?
For a 70 kg adult that is about 2.1 mg per day, delivered continuously over the 48-hour infusion window.
Sources
- Serelaxin and acute heart failure (PubMed search) ↗
- Serelaxin and the RELAX-AHF trials (PubMed search) ↗
Categories: Healing & Recovery · Status: Investigational. This page is educational and for laboratory research use only; it is not medical advice.